Is this SDS the latest revision?

This Safety Data Sheet was issued by GlaxoSmithKline on 24 May 2018 under GHS/CLP. ISDSS syncs its database regularly to keep documents current.

Do I need to register to download this SDS?

Yes, a free ISDSS account is required to download the PDF. Registration takes under two minutes and gives you access to over 1.5 million Safety Data Sheets. Once registered, you can also save documents to your personal library for quick access.

Who is responsible for providing an SDS?

The manufacturer, importer or supplier that places the substance on the market is responsible for providing a current Safety Data Sheet to downstream users, free of charge.

Can I use this SDS as my COSHH risk assessment?

No. An SDS provides the hazard information you need, but a COSHH assessment must consider how the substance is actually used in your workplace. The matching Chemical Risk Assessment (CRA) on this page is a starting point you should adapt to your own tasks and controls.

Safety Data SheetChemical Risk Assessment

Retrovir Capsules

by GlaxoSmithKline

SDS · PDF, approx. 220 KB CRA · PDF, approx. 180 KB

Retrovir Capsules is supplied by GlaxoSmithKline under product code RETROVIR CAPSULES 100 MG, RETROVIR CAPSULES 250 MG, RETROVIR CAPSULAS, RETROVIR GELULES, RETROVIR KAPSELI, RETROVIR KAPS ELN, RETROVIR KAPSLAR, RETROVIR KAPSLER, RETROVIR KAPSUL, RETROVIR KAPSU LAS, RETROVIR KAPSULE, RETROVIR KAPSULKI, ZIDOVUDINE CAPSULES, HARD, ZID OVUDINE, FORMULATED PRODUCT. This page provides both the Safety Data Sheet (SDS) and the Chemical Risk Assessment (CRA) for this substance, under GHS/CLP regulations for UK workplace use under COSHH. The full SDS and CRA documents are available to download above.

This SDS was last revised on 24 May 2018. The matching CRA is updated in line with SDS revisions. Workplaces handling this substance should retain a current SDS and risk assessment for the duration of use.

Language: English
Regulation: GHS/CLP
Revision Date: 24 May 2018
Signal Word: WARNING
Product Code: RETROVIR CAPSULES 100 MG, RETROVIR CAPSULES 250 MG, RETROVIR CAPSULAS, RETROVIR GELULES, RETROVIR KAPSELI, RETROVIR KAPS ELN, RETROVIR KAPSLAR, RETROVIR KAPSLER, RETROVIR KAPSUL, RETROVIR KAPSU LAS, RETROVIR KAPSULE, RETROVIR KAPSULKI, ZIDOVUDINE CAPSULES, HARD, ZID OVUDINE, FORMULATED PRODUCT
CAS Number: 30516-87-1

Switch between the Safety Data Sheet and the Chemical Risk Assessment for this substance.

Hazards at a GlanceFrom the Safety Data Sheet

Signal Word: WARNING

Hazard Statements (H-phrases)

+548+EEC: See full Safety Data Sheet for the hazard statement wording.

Need the full hazard breakdown? Precautionary statements, first aid, physical properties and exposure controls are in the full SDS PDF.

Common QuestionsAbout this Safety Data Sheet

Chemical Risk Assessment SummaryFrom the Chemical Risk Assessment

Assessment Summary

This Chemical Risk Assessment is derived from the Safety Data Sheet for Retrovir Capsules issued by GlaxoSmithKline on 24 May 2018 It presents the substance's hazards organised by risk level, with the relevant regulatory statements and recommended controls for each.

Hazard PreviewA snapshot of substance hazards and controls

Note: This is a preview of the substance's hazards. A substance commonly carries more hazards. Download the full Chemical Risk Assessment for more information.

Recommended Control MeasuresKey PPE and handling controls

Need to download the Chemical Risk Assessment? The full CRA PDF includes all hazard classifications, regulatory statements and recommended controls.

Common QuestionsAbout this Risk Assessment

Free with ISDSS

Manage Your SDS Library

Build a personal library of every SDS your workplace uses. Search, download and access documents any time you need them.

Retrovir Capsules

Need help with Safety Data Sheets? You've come to the right place!

Follow Us